Literature DB >> 17113161

Anti-ganglioside complex antibodies associated with severe disability in GBS.

K Kaida1, D Morita, M Kanzaki, K Kamakura, K Motoyoshi, M Hirakawa, S Kusunoki.   

Abstract

Ganglioside complexes (GSCs) are known as target antigens in Guillain-Barré syndrome (GBS). To elucidate the clinical importance of the anti-GSC antibodies in GBS, we investigated serum antibodies to GSCs containing two of the gangliosides, GM1, GD1a, GD1b and GT1b, and analyzed clinical features of anti-GSC-positive GBS patients. Thirty-nine (17%) of 234 GBS patients had IgG anti-GSC antibodies. Anti-GSC-positive GBS had antecedent gastrointestinal infection and lower cranial nerve deficits more frequently than control GBS. The presence of antibody specificity to GD1a/GD1b and/or GD1b/GT1b was significantly associated with severe disability and a requirement for mechanical ventilation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17113161     DOI: 10.1016/j.jneuroim.2006.09.013

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  22 in total

1.  Preceding infections and anti-ganglioside antibody profiles assessed by a dot immunoassay in 306 French Guillain-Barré syndrome patients.

Authors:  Christiane Caudie; Arnaud Quittard Pinon; Didier Taravel; Valérie Sivadon-Tardy; David Orlikowski; Flore Rozenberg; Tarek Sharshar; Jean Claude Raphaël; Jean Louis Gaillard
Journal:  J Neurol       Date:  2011-04-24       Impact factor: 4.849

2.  Anti-ganglioside antibody-mediated activation of RhoA induces inhibition of neurite outgrowth.

Authors:  Gang Zhang; Helmar C Lehmann; Sowmia Manoharan; Mohammedali Hashmi; Sangwoo Shim; Guo-Li Ming; Ronald L Schnaar; Pablo H Lopez; Nataliia Bogdanova; Kazim A Sheikh
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

Review 3.  Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction.

Authors:  Jaap J Plomp; Hugh J Willison
Journal:  J Physiol       Date:  2009-06-29       Impact factor: 5.182

4.  Antibodies to single glycolipids and glycolipid complexes in Guillain-Barré syndrome subtypes.

Authors:  Nortina Shahrizaila; Norito Kokubun; Setsu Sawai; Thirugnanam Umapathi; Yee-Cheun Chan; Satoshi Kuwabara; Koichi Hirata; Nobuhiro Yuki
Journal:  Neurology       Date:  2014-06-11       Impact factor: 9.910

Review 5.  Dissecting the Role of Anti-ganglioside Antibodies in Guillain-Barré Syndrome: an Animal Model Approach.

Authors:  Pallavi Asthana; Joaquim Si Long Vong; Gajendra Kumar; Raymond Chuen-Chung Chang; Gang Zhang; Kazim A Sheikh; Chi Him Eddie Ma
Journal:  Mol Neurobiol       Date:  2015-09-15       Impact factor: 5.590

Review 6.  Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains.

Authors:  Adriane Regina Todeschini; Sen-itiroh Hakomori
Journal:  Biochim Biophys Acta       Date:  2007-10-22

Review 7.  Gangliosides in cell recognition and membrane protein regulation.

Authors:  Pablo H H Lopez; Ronald L Schnaar
Journal:  Curr Opin Struct Biol       Date:  2009-07-14       Impact factor: 6.809

8.  Anti-GM2 ganglioside antibodies are a biomarker for acute canine polyradiculoneuritis.

Authors:  Angie Rupp; Francesc Galban-Horcajo; Ezio Bianchi; Maurizio Dondi; Jacques Penderis; Joanna Cappell; Karl Burgess; Kaspar Matiasek; Rhona McGonigal; Hugh J Willison
Journal:  J Peripher Nerv Syst       Date:  2013-03       Impact factor: 3.494

9.  An update on pathobiologic roles of anti-glycan antibodies in Guillain-Barré syndrome.

Authors:  Kazim A Sheikh; Gang Zhang
Journal:  F1000 Biol Rep       Date:  2010-03-25

10.  Ganglioside GM2/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82/cMet-mediated pathway.

Authors:  Adriane Regina Todeschini; Jose Nilson Dos Santos; Kazuko Handa; Sen-itiroh Hakomori
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.